CD274 and neoplasm: To overcome this challenge, several response markers and comprehensive immune signatures have been exploited to select patients who would benefit from ICB, including PD-L1 expression status10–13, microsatellite instability (MSI)14 and tumor mutational burden (TMB)15–17.